文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

FRA-1 作为乳腺癌 EMT 和转移的调节因子。

FRA-1 as a Regulator of EMT and Metastasis in Breast Cancer.

机构信息

Institute of Genetics and Biophysics "A. Buzzati Traverso", Consiglio Nazionale delle Ricerche (CNR), Via Pietro Castellino, 111, 80131 Naples, Italy.

出版信息

Int J Mol Sci. 2023 May 5;24(9):8307. doi: 10.3390/ijms24098307.


DOI:10.3390/ijms24098307
PMID:37176013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10179602/
Abstract

Among FOS-related components of the dimeric AP-1 transcription factor, the oncoprotein FRA-1 (encoded by ) is a key regulator of invasion and metastasis. The well-established FRA-1 pro-invasive activity in breast cancer, in which is overexpressed in the TNBC (Triple Negative Breast Cancer)/basal subtypes, correlates with the FRA-1-dependent transcriptional regulation of EMT (Epithelial-to-Mesenchymal Transition). After summarizing the major findings on FRA-1 in breast cancer invasiveness, we discuss the FRA-1 mechanistic links with EMT and cancer cell stemness, mediated by transcriptional and posttranscriptional interactions between /FRA-1 and EMT-regulating transcription factors, miRNAs, RNA binding proteins and cytokines, along with other target genes involved in EMT. In addition to the FRA-1/AP-1 effects on the architecture of target promoters, we discuss the diagnostic and prognostic significance of the EMT-related FRA-1 transcriptome, along with therapeutic implications. Finally, we consider several novel perspectives regarding the less explored roles of FRA-1 in the tumor microenvironment and in control of the recently characterized hybrid EMT correlated with cancer cell plasticity, stemness, and metastatic potential. We will also examine the application of emerging technologies, such as single-cell analyses, along with animal models of TNBC and tumor-derived CTCs and PDXs (Circulating Tumor Cells and Patient-Derived Xenografts) for studying the FRA-1-mediated mechanisms in in vivo systems of EMT and metastasis.

摘要

在二聚体 AP-1 转录因子的 FOS 相关成分中,癌蛋白 FRA-1(由 编码)是侵袭和转移的关键调节因子。在乳腺癌中,FRA-1 具有明确的促侵袭活性,在 TNBC(三阴性乳腺癌)/基底亚型中过表达,与 FRA-1 依赖性 EMT(上皮-间充质转化)转录调控相关。在总结了 FRA-1 在乳腺癌侵袭性中的主要发现后,我们讨论了 FRA-1 与 EMT 和癌细胞干性的机制联系,这是通过 /FRA-1 与 EMT 调节转录因子、miRNA、RNA 结合蛋白和细胞因子之间的转录和转录后相互作用介导的,以及 EMT 涉及的其他靶基因。除了 FRA-1/AP-1 对靶启动子结构的影响外,我们还讨论了 EMT 相关 FRA-1 转录组的诊断和预后意义,以及治疗意义。最后,我们考虑了关于 FRA-1 在肿瘤微环境中以及在控制最近描述的与癌细胞可塑性、干性和转移潜力相关的混合 EMT 方面的一些较少探索的作用的几个新观点。我们还将研究新兴技术的应用,例如单细胞分析,以及 TNBC 动物模型和肿瘤衍生的循环肿瘤细胞 (CTC) 和患者来源的异种移植 (PDX),以研究 EMT 和转移的体内系统中的 FRA-1 介导机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4b2/10179602/4f2e5112d054/ijms-24-08307-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4b2/10179602/dd7a2b7a4282/ijms-24-08307-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4b2/10179602/a64defa6a6a9/ijms-24-08307-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4b2/10179602/119eb967eb53/ijms-24-08307-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4b2/10179602/4f88ffff68a5/ijms-24-08307-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4b2/10179602/4f2e5112d054/ijms-24-08307-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4b2/10179602/dd7a2b7a4282/ijms-24-08307-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4b2/10179602/a64defa6a6a9/ijms-24-08307-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4b2/10179602/119eb967eb53/ijms-24-08307-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4b2/10179602/4f88ffff68a5/ijms-24-08307-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4b2/10179602/4f2e5112d054/ijms-24-08307-g005.jpg

相似文献

[1]
FRA-1 as a Regulator of EMT and Metastasis in Breast Cancer.

Int J Mol Sci. 2023-5-5

[2]
The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications' door.

Oncogene. 2020-5-8

[3]
Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression.

Cell Death Differ. 2015-2

[4]
The Fra-1/AP-1 Oncoprotein: From the "Undruggable" Transcription Factor to Therapeutic Targeting.

Cancers (Basel). 2022-3-14

[5]
Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition.

Carcinogenesis. 2015-4

[6]
miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer.

Pathol Res Pract. 2019-4

[7]
MiR-1976 knockdown promotes epithelial-mesenchymal transition and cancer stem cell properties inducing triple-negative breast cancer metastasis.

Cell Death Dis. 2020-7-3

[8]
Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer.

Cancer Res. 2014-5-15

[9]
Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-β-SMAD3 pathway in non-small cell lung adenocarcinoma.

Proc Natl Acad Sci U S A. 2014-9-9

[10]
Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.

Br J Cancer. 2014-2-25

引用本文的文献

[1]
Noncoding RNAs as regulators of FOSL1 in cancer.

Front Immunol. 2025-8-1

[2]
Schwann cell reprogramming via EMT-like program following peripheral nerve injury and during nerve regeneration.

Front Cell Dev Biol. 2025-7-9

[3]
FRA1 drives melanoma metastasis through an actionable transcriptional network.

bioRxiv. 2025-6-10

[4]
Pioneering new enhancers by GATA3: role of facilitating transcription factors and chromatin remodeling.

Nucleic Acids Res. 2025-6-6

[5]
Deep-learning-enabled multi-omics analyses for prediction of future metastasis in cancer.

bioRxiv. 2025-5-22

[6]
Non-coding RNAs as key regulators of epithelial-mesenchymal transition in breast cancer.

Front Cell Dev Biol. 2025-3-25

[7]
Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers.

Mol Cancer. 2025-3-14

[8]
FOSL1 drives the malignant progression of pancreatic cancer cells by regulating cell stemness, metastasis and multidrug efflux system.

J Transl Med. 2025-3-4

[9]
Histone H3E50K remodels chromatin to confer oncogenic activity and support an EMT phenotype.

NAR Cancer. 2025-2-3

[10]
Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial-Mesenchymal Transition.

Cancers (Basel). 2025-1-12

本文引用的文献

[1]
Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.

J Med Chem. 2022-11-24

[2]
Research progress on RNA-binding proteins in breast cancer.

Front Oncol. 2022-8-18

[3]
HOXA11-AS1 Promotes PD-L1-Mediated Immune Escape and Metastasis of Hypopharyngeal Carcinoma by Facilitating PTBP1 and FOSL1 Association.

Cancers (Basel). 2022-7-29

[4]
FRA-1: A key factor regulating signal transduction of tumor cells and a potential target molecule for tumor therapy.

Biomed Pharmacother. 2022-6

[5]
The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer.

Semin Cancer Biol. 2022-11

[6]
Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis.

Nat Cell Biol. 2022-4

[7]
Potential Target Analysis of Triptolide Based on Transcriptome-Wide mA Methylome in Rheumatoid Arthritis.

Front Pharmacol. 2022-3-25

[8]
The Fra-1/AP-1 Oncoprotein: From the "Undruggable" Transcription Factor to Therapeutic Targeting.

Cancers (Basel). 2022-3-14

[9]
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.

Nat Cancer. 2022-2

[10]
Role of the Transcription Factor FOSL1 in Organ Development and Tumorigenesis.

Int J Mol Sci. 2022-1-28

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索